KLK3 and neoplasm: Five (24%) of 21 patients had an objective partial response using the prespecified response criteria of: ≥30% decrease in measurable disease according to the Response Evaluation Criteria in Solid Tumors v.1.1, prostate-specific antigen (PSA) decline ≥50% confirmed ≥4 weeks later, and/or conversion of circulating tumour cell (CTC) count from ≥5 per 7.5 ml of blood at baseline to <5 per 7.5 ml of blood at nadir (Fig. 4a–c).